2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|February 17, 2022
ProBioGen Inks License Agreement Deal with AstraZeneca
Author(s)Pharmaceutical Technology Editors
The deal between ProBioGen and AstraZeneca will allow AstraZeneca to use ProBioGen’s GlymaxX technology.
Advertisement
ProBioGen, a contract manufacturing and development organization, announced on Feb. 11, 2022, that it had come to an agreement with AstraZeneca to license out its GlymaxX technology. According to a company press release, GlymaxX improves target cell killing orchestrated by natural killer cells, enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).
According to the release, GlymaxX prevents the addition of the sugar fucose in the N-linked antibody carbohydrate part by introducing an enzyme which deflects the cellular pathway of fucose biosynthesis. The absence of fucose enhances ADCC activity for antibodies directed against cancer and infectious diseases, making it ideal for drug discovery purposes. Additionally, one unique advantage of GlymaxX is that it can use the same modified cell line to produce antibodies of varying levels of fucosylation.
"We are delighted that AstraZeneca decided to implement our technology, which has shown great potential in making molecules more potent and efficient." said Gabriele Schneider, chief business officer, ProBioGen, in the press release.
Source:
Advertisement
Related to this article
Lilly is set to acquire Merida Biosciences for up to $2.875B, gaining a precision autoantibody-degrading platform led by phase 1 candidate MER511.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Advertisement
Advertisement